Amy is a managing partner in the New York office and focuses on investments in healthcare companies.
She currently serves as executive chair of SQZ Biotech, as well as Lyndra Therapeutics, where she was co-founder and the company’s initial CEO. She also represents Polaris as a director of Kallyope, Volastra, Thirty Madison and ByHeart. Amy joined Polaris in 2014, at which time she assumed the role of CEO of Arsia Therapeutics, a Polaris-backed company later acquired by Eagle Pharmaceuticals. She also manages the Polaris Innovation Fund which was formed in 2017.
Prior to joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and was instrumental in its sale to Nestle for $11.85 billion in 2012. Soon after, Schulman became the president of Pfizer Consumer Healthcare.
Schulman has received numerous awards including 2019 PharmaVoice 100, Xconomy’s 2017 Newcomer Award, Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She serves on the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) and Mount Sinai Hospital, and served as a Senior Lecturer at Harvard Business School. She is also a member of Singapore’s Health and Biomedical Sciences International Advisory Council.
She is a Phi Beta Kappa graduate of Wesleyan University with a joint degree in philosophy and english and earned her J.D. from Yale Law School.
How do I contact Amy W. Schulman?
Has Amy W. Schulman been buying or selling shares of SQZ Biotechnologies?
Amy W. Schulman has not been actively trading shares of SQZ Biotechnologies in the last ninety days. Most recently, on Monday, December 13th, Amy W. Schulman bought 370 shares of SQZ Biotechnologies stock. The stock was acquired at an average cost of $109.10 per share, with a total value of $40,367.00. Learn More on Amy W. Schulman's trading history.
